Acid-Responsive Multifunctional Zeolitic Imidazolate Framework-8 (ZIF-8) Nanocomposites for Tumor Chemo-Photothermal Synergistic Therapy.

Weiwei Liu, Farouk Semcheddine, Hui Jiang, Xuemei Wang

Journal: Bioconjugate chemistry 2022;33(7):1405-1414

PMID: 35797716

Abstract

Camptothecin (CPT), a broad-spectrum anticancer drug, has been extensively used clinically. However, its hydrophobic properties seriously hinder its antitumor therapeutic effect. Herein, we synthesized acid-degradable FeO@poly(vinylpyrrolidone) (FeO@PVP)/gold nanoclusters@zeolitic imidazolate framework-8 composite nanoparticles (ZIF-8CNPs) via a facile method and utilized them as carriers to efficiently load CPT. The excellent fluorescence properties of gold nanoclusters (AuNCs) and the photothermal properties of FeO@poly(vinylpyrrolidone) (FeO@PVP) endowed the nanocomposites with excellent cell imaging and photothermal functions. In addition, the surface modification of the composite nanoparticles with folic acid-grafted bovine serum albumin (FA-BSA) enables them to efficiently target tumor cells. Once FA-BSA/ZIF-8CNPs-CPT are taken up by tumor cells and irradiated with a near-infrared laser, the nanoparticles show a highly effective inhibitory effect against various tumor cells through a chemo-photothermal synergistic effect. Hence, it is conceivable that this acid-responsive multifunctional ZIF-8 nanocomposite has promising bioapplication prospects in cancer treatment.

Address: State Key Laboratory of Bioelectronics, National Demonstration Center for Experimental Biomedical Engineering Education, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.; School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210096, China.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.